UTRS (Minerva Surgical) Total Stockholders Equity: $20.26 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Minerva Surgical Total Stockholders Equity?

Minerva Surgical UTRS -99.00% Total Stockholders Equity is $20.26 Mil as of Sep. 2023.

Minerva Surgical's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $20.26 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Minerva Surgical's Book Value per Share for the quarter that ended in Sep. 2023 was $2.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Minerva Surgical's Debt-to-Equity for the quarter that ended in Sep. 2023 was 2.15.

Minerva Surgical  (OTCPK:UTRS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Minerva Surgical's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(20.255-0)/8.879
=2.28

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Minerva Surgical's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(12.272 + 31.279) / 20.255
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Total Stockholders Equity Related Terms

Minerva Surgical Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical Total Stockholders Equity Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
-204.52 -221.81 44.10 17.18

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.54 17.18 34.07 26.59 20.26
What does a Total Stockholders Equity of $20.26 Mil mean?
Minerva Surgical (UTRS) has a Total Stockholders Equity of $20.26 Mil as of Sep. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Minerva Surgical and its competitors.
Is Minerva Surgical's Total Stockholders Equity too high?
Minerva Surgical's current Total Stockholders Equity is $20.26 Mil.
How does Minerva Surgical's Total Stockholders Equity compare to PAVM and ELUT?
Minerva Surgical's Total Stockholders Equity of $20.26 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Minerva Surgical and its competitors. Minerva Surgical's current Total Stockholders Equity is $20.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current Total Stockholders Equity of $20.26 Mil. The current Total Stockholders Equity is $20.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current Total Stockholders Equity is $20.26 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.